ESPR
Esperion Therapeutics Inc
NASDAQ: ESPR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$3.12
+0.32% today
Updated 2026-06-02
Market cap
$805.76M
P/E ratio
0.00
P/S ratio
1.93x
EPS (TTM)
$0.00
Dividend yield
—
52W range
$1 – $4
Volume
13.1M
WallStSmart proprietary scores
32
out of 100
Grade: F
Strong Sell
Investment rating
7.3
Growth
B+5.5
Quality
C+3.5
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-3.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$3.19
+2.24%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy3 Buy1 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 23.20% QoQ
+ Debt/equity -0.82x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -3.93 — distress zone
- Thin margins at -1.78%
- Negative free cash flow $-27.91M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $75.47M | $116.33M | $332.31M | $403.13M | $418.24M |
| Net income | $-233.66M | $-209.25M | $-51.74M | $-22.68M | $-25.20M |
| EPS | — | — | — | — | $0.00 |
| Free cash flow | $-174.83M | $-135.49M | $-23.97M | $-13.28M | $-27.91M |
| Profit margin | -309.58% | -179.87% | -15.57% | -5.63% | -1.78% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-17 | LOOKER, BENJAMIN | Sale | 5,708 | $2.70 |
| 2026-03-17 | KOENIG, SHELDON L. | Sale | 25,578 | $2.72 |
| 2026-03-17 | HALLADAY, BENJAMIN | Sale | 6,424 | $2.71 |
Peer comparison
Smart narrative
Esperion Therapeutics Inc trades at $3.12. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -3.93, it sits in the distress. TTM revenue stands at $418.24M. with profit margins at -1.78%.
Frequently asked questions
What is Esperion Therapeutics Inc's stock price?
Esperion Therapeutics Inc (ESPR) trades at $3.12, on a P/S of 1.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Esperion Therapeutics Inc overvalued?
Esperion Therapeutics Inc carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Esperion Therapeutics Inc (ESPR)?
The 12-month analyst consensus target is $3.19, about 2.2% above the current $3.12. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Esperion Therapeutics Inc's revenue?
Esperion Therapeutics Inc's trailing twelve-month revenue is $418.24M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Esperion Therapeutics Inc's Altman Z-Score is -3.93, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.93x
ROE-260.80%
Beta1.07
50D MA$2.66
200D MA$2.97
Shares out0.26B
Float0.26B
Short ratio—
Avg volume13.1M
Performance
1 week+0.00%
1 month+0.64%
3 months+28.69%
YTD-15.14%
1 year—
3 years—
5 years—